Related Experiment Video
Updated: Jan 18, 2026
![Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F68356.jpg&w=3840&q=50)
Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
Published on: April 25, 2025
Afatinib-based combination regimens for the treatment of solid tumors: rationale, emerging strategies and recent
Jaafar Bennouna1, Shanti Ricardo Moreno Vera2
1Institut de Cancérologie de l'Ouest, Nantes-Angers, France.
Abstract:
In oncology, there is a clinical need for novel combination therapy regimens that maximize efficacy and delay resistance to individual treatment modalities. Given the role of aberrant ErbB receptor signaling in the pathogenesis of many human cancers, there is rationale for incorporating afatinib, an irreversible pan-ErbB tyrosine kinase inhibitor, into such combinations. This review focuses on: pharmacological properties of afatinib that facilitate its use in combination; preclinical rationale for the combination of afatinib with other agents; and recently completed, and ongoing, clinical trials of afatinib-based combinations across tumor types. Based on these data, we emphasize a number of areas of high unmet medical need that could benefit from afatinib-based combinations, including patients with relapsed/refractory non-small-cell lung cancer.
Insights
Afatinib, an irreversible pan-ErbB tyrosine kinase inhibitor, shows promise in combination therapies for various cancers. Clinical trials are exploring afatinib combinations for unmet needs, especially in non-small-cell lung cancer.
Area of Science:
- Oncology
- Pharmacology
- Cancer Research
Background:
- Aberrant ErbB receptor signaling drives many human cancers.
- There is a need for novel combination therapies to improve efficacy and overcome resistance.
- Afatinib is an irreversible pan-ErbB tyrosine kinase inhibitor with potential in combination regimens.
Purpose of the Study:
- To review the pharmacological properties of afatinib relevant to combination therapy.
- To examine the preclinical rationale for combining afatinib with other anticancer agents.
- To summarize completed and ongoing clinical trials of afatinib-based combinations.
Main Methods:
- Literature review of afatinib's properties and preclinical studies.
- Systematic review of clinical trials involving afatinib combinations.
- Analysis of data from completed and ongoing clinical trials.
Main Results:
- Afatinib's pharmacological profile supports its use in combination therapies.
- Preclinical data provide a strong rationale for combining afatinib with various agents.
- Clinical trials are evaluating afatinib combinations across multiple tumor types, with promising results in certain settings.
Conclusions:
- Afatinib-based combination therapies represent a promising strategy for managing various cancers.
- These combinations address significant unmet medical needs, particularly in relapsed/refractory non-small-cell lung cancer.
- Further clinical investigation is warranted to optimize afatinib combination regimens.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers
01:27Tumor Immunotherapy